The case is set to be a big test of China's new bankruptcy law, which came into effect in 2007 but has rarely been applied to overseas-listed companies with assets in China.
Dr Andrew Herxheimer wanted to test whether, in the case of Seroxat, a widely-used antidepressant, the scheme was set up to respond to reports of side-effects.